69716-04-7

Basic information

• Product Name: 2-(6-HYDROXY-1-BENZOFURAN-3-YL) ACETIC ACID, 97
• Synonyms: 2-(6-HYDROXY-1-BENZOFURAN-3-YL) ACETIC ACID, 97;2-(6-Hydroxy-1-benzofuran-3-yl)aceticacid;3-Benzofuranacetic acid, 6-hydroxy-;(6-Hydroxybenzofuran-3-yl)acetic acid;2-(6-HYDROXY-1-BENZOFURAN-3-YL) ACETIC ACID, 97-3
• CAS NO: 69716-04-7
• Molecular Formula: C₁₀H₈O₄
• Molecular Weight: 192.16812
• Mol File: 69716-04-7.mol
• Article Data: 16

Chemical Properties

• Melting Point: 139-140℃
• Boiling Point: 251.5±9.0℃ (760 Torr)
• Flash Point: 105.9±18.7℃
• Appearance: /
• Density: 1.453±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.12±0.30(Predicted)
• CAS DataBase Reference: 2-(6-HYDROXY-1-BENZOFURAN-3-YL) ACETIC ACID, 97(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(6-HYDROXY-1-BENZOFURAN-3-YL) ACETIC ACID, 97(69716-04-7)
• EPA Substance Registry System: 2-(6-HYDROXY-1-BENZOFURAN-3-YL) ACETIC ACID, 97(69716-04-7)

Safety Data

• Hazardous Substances Data: 69716-04-7(Hazardous Substances Data)

Usage

Description

2-(6-Hydroxy-1-benzofuran-3-yl) Acetic Acid, 97 is an organic compound that serves as a key reactant in the synthesis of various pharmaceutical compounds. It is characterized by its unique chemical structure, which includes a benzofuran ring and a carboxylic acid group, making it a versatile building block for the development of new drugs and therapeutic agents.

Uses

Used in Pharmaceutical Industry:
2-(6-Hydroxy-1-benzofuran-3-yl) Acetic Acid, 97 is used as a reactant in the synthesis of dihydrobenzofuran derivatives, which have potential applications as potent and orally available GPR40/FFA1 agonists. These agonists play a crucial role in modulating glucose homeostasis and insulin secretion, making them valuable for the treatment of type 2 diabetes and related metabolic disorders.
In the synthesis process, 2-(6-Hydroxy-1-benzofuran-3-yl) Acetic Acid, 97 is combined with other chemical moieties to form the desired dihydrobenzofuran compound. 2-(6-HYDROXY-1-BENZOFURAN-3-YL) ACETIC ACID, 97, 6-[4''-(2-ethoxyethoxy)-2'',6''-dimethylbiphenyl-3-yl]methoxy-2,3-dihydro-1-benzofuran-3-yl)acetic acid, exhibits high affinity and selectivity for the GPR40/FFA1 receptor, making it a promising candidate for further research and development in the field of diabetes management.
Overall, 2-(6-Hydroxy-1-benzofuran-3-yl) Acetic Acid, 97 is an essential component in the development of innovative pharmaceutical agents, particularly in the area of diabetes treatment. Its unique chemical properties and reactivity make it a valuable building block for the synthesis of potent and effective GPR40/FFA1 agonists, which have the potential to improve the lives of millions of people living with type 2 diabetes and related metabolic conditions.

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 108-46-3 recorcinol 
• 161798-25-0 4-(bromomethyl)-7-hydroxy-2H-chromen-2-one 
• 25392-41-0 4-chloromethyl-7-hydroxycoumarin 

Downstream Products

• 805250-17-3 (6-hydroxy-2,3-dihydro-benzofuran-3-yl)-acetic acid methyl ester 
• 1356599-30-8 {6-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]-2,3-dihydro-benzofuran-3-yl}acetic acid 
• 1356600-64-0 methyl {6-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]-2,3-dihydro-benzofuran-3-yl}acetate 
• 1000414-38-9 methyl ((3S)-6-hydroxy-2,3-dihydro-1-benzofuran-3-yl)acetate 
• 1252592-54-3 benzyl 2-(6-(benzyloxyl)benzofuran-3-yl)acetate 
• 1252592-55-4 2-[6-(benzyloxy)benzofuran-3-yl]ethanol 
• 1252592-59-8 3-{2-[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]ethyl}benzofuran-6-yl sulfamate 
• 1252592-58-7 4-{[2-(6-hydroxybenzofuran-3-yl)ethyl](4H-1,2,4-triazol-4-yl)amino}benzonitrile 
• 1252592-57-6 4-({2-[6-(benzyloxy)benzofuran-3-yl]ethyl}(4H-1,2,4-triazol-4-yl)amino)benzonitrile 
• 1252592-56-5 2-[6-(benzyloxy)benzofuran-3-yl]ethyl 4-methylbenzenesulfonate 
• 945774-05-0 C₂₆H₂₁F₃O₅ 
• 945774-04-9 C₂₆H₂₁F₃O₅ 
• 945774-03-8 C₂₆H₂₁F₃O₅ 
• 779205-37-7 {6-[5-(4-Trifluoromethyl-phenyl)-isoxazol-3-ylmethoxy]-benzofuran-3-yl}-acetic acid methyl ester 

Relevant articles and documents

Compound with glucose-reducing and lipid-regulating effects as well as preparation and application thereof

The invention discloses a compound with glucose-reducing and lipid-regulating effects as well as a preparation and application thereof. The compound with glucose-reducing and lipid-regulating effectsis a compound with structures as shown in a formula I and a formula II and a pharmaceutically acceptable salt, wherein the structures as shown in the formula I and the formula II are specifically shown in the specification. The preparation is a tablet, a capsule, powder, a pill or an injection prepared by adding pharmaceutically acceptable auxiliary materials into the compound with the glucose-reducing and lipid-regulating effects. The application is the application of the compound with the glucose-reducing and lipid-regulating effects in preparing an FFA1/PPARdelta dual agonist. The application is the application of the compound with the glucose-reducing and lipid-regulating effects in preparation of drugs for preventing and/or treating glucose metabolic disorder and/or lipid metabolic disorder diseases. The compound and the medicinal salt thereof can be potentially used for treating or preventing diabetes, hyperlipidemia, fatty liver and other related metabolic syndromes, and have wide development prospects.

Synthesis and preliminary evaluation of benzofuran-oxadiazole conjugates as potential antitubercular agents

In the present study, a series of benzofuran-oxadiazole conjugates 7(a-o) was designed, synthesized and characterized through IR,1H NMR,13C NMR and mass spectral data. All the compounds were screened for preliminary antitubercular activity against Mycobacterium phlei and Mycobacterium tuberculosis H37RV. Among all the target compounds, the compound possessing chlorine (7k, MIC 1.56 μg/mL) and bromine (7m, MIC 1.56 μg/mL) on 6th position of benzofuran showed highest activity against Mycobacterium phlei. Whereas, bromine on either 5th position (7l, MIC 3.125 μg/mL) or 6th position (7m MIC 3.125 μg/mL) on benzofuran exhibited highest activity for Mycobacterium tuberculosis (H37 RV).

Aromatic polycyclic carboxylic acid derivatives

The invention belongs to the field of medicine technology, and specifically relates to an aromatic polycyclic carboxylic acid derivative GPR40 receptor agonist with a general formula (I), a pharmaceutically acceptable salt thereof, and an ester or stereoi